Rapamycin for Longevity: Complete Guide

Of all the pharmacological interventions being studied for aging, rapamycin has the strongest evidence base. It's the only drug that has consistently extended lifespan across multiple species — yeast, worms, flies, and mice — and the only one with a plausible mechanistic story for how it does so. It's also a prescription immunosuppressant with real side effects, and using it off-label for longevity is firmly experimental. This guide is the evidence-based picture as of 2026.

We have no affiliate products to recommend here — rapamycin is prescription-only and not sold as a supplement. This guide is educational only and not medical advice.

What is rapamycin?

Rapamycin (also known as sirolimus) was discovered in the 1970s in a soil sample from Easter Island (Rapa Nui — hence the name), isolated from the bacterium Streptomyces hygroscopicus. It was originally investigated as an antifungal but found to have potent immunosuppressive and anti-proliferative properties.

Today, rapamycin is FDA-approved for:

• Preventing organ transplant rejection (kidney, primarily).
• Coating coronary stents (to prevent restenosis).
• Treating lymphangioleiomyomatosis (LAM), a rare lung disease.

Its off-label use for longevity — typically in low weekly doses — has exploded in the longevity community since the mid-2010s, driven by consistent lifespan-extension data in mice and a small but growing body of human evidence for safety at low intermittent doses.

How rapamycin works: mTOR inhibition

Rapamycin's mechanism was worked out in the 1990s: it binds to a protein called FKBP12, and the resulting complex inhibits a kinase that came to be called mTOR (mechanistic target of rapamycin). mTOR is the master regulator of cellular growth — it senses nutrient availability (especially amino acids, especially leucine), growth factors (insulin, IGF-1), and energy status, then orchestrates cellular programs: protein synthesis, cell growth, autophagy suppression, lipid synthesis.

When nutrients are abundant, mTOR is active and cells grow. When nutrients are scarce (fasting, caloric restriction), mTOR is suppressed and cells shift into "maintenance mode": autophagy ramps up (clearing damaged proteins and organelles), protein synthesis slows, inflammation falls. This mTOR-suppressed state is associated with longer lifespan across species.

Rapamycin pharmacologically mimics the mTOR-suppressed state — without requiring fasting or caloric restriction. This is the mechanistic basis for its lifespan effects. The connection to other longevity interventions is direct:

• Caloric restriction and fasting suppress mTOR naturally (via lower amino acids, lower insulin). See our fasting guide.
• Metformin indirectly inhibits mTOR via AMPK activation. See our metformin guide.
• Protein restriction (especially methionine) lowers mTOR signaling. See our diet guide.
• Rapamycin directly inhibits mTOR.

mTOR has two distinct complexes: mTORC1 (rapamycin-sensitive) and mTORC2 (rapamycin-insensitive, at least acutely). Chronic rapamycin can inhibit mTORC2, which is thought to drive some of its side effects (insulin resistance). Intermittent dosing is designed to suppress mTORC1 while sparing mTORC2.

Animal evidence: lifespan extension

Rapamycin is the gold-standard lifespan-extension drug in laboratory animals:

• Yeast — rapamycin extends replicative lifespan.
• Worms (C. elegans) — rapamycin extends lifespan.
• Fruit flies — rapamycin extends lifespan.
• Mice — the seminal 2009 NIA Interventions Testing Program (ITP) trial showed rapamycin extended median lifespan in mice by 14% in females and 9% in males, even when started late in life (600 days old). Multiple subsequent trials have confirmed this, with extension up to 25–30% in some protocols.
• Dogs — an ongoing trial (the Dog Aging Project) is testing rapamycin in companion dogs; early results suggest improved cardiac function.

This cross-species consistency is what makes rapamycin the most credible pharmacological anti-aging candidate. No other drug has shown this kind of lifespan extension across this many organisms. The question is whether it works in humans, and at what dose, and with what risk.

Human evidence: what we know and don't know

There are no published human trials of rapamycin for lifespan extension. The relevant evidence comes from:

• Transplant patients on chronic rapamycin — they have lower rates of some cancers (interesting) but higher rates of infection and metabolic side effects (concerning). However, these patients take daily high doses for years; longevity use is typically low weekly doses.
• Small off-label longevity trials — several small trials (Mannick et al. 2014, 2018) tested rapamycin (everolimus) at low weekly doses in elderly adults and showed improved immune response to flu vaccine and reduced infection rates. This is encouraging evidence for low-dose rapamycin safety and immune benefit.
• Observational data — there's no organized cohort of off-label rapamycin users with proper outcome tracking, though this is beginning to change.

The honest state: rapamycin has the strongest animal evidence of any anti-aging drug, plausible mechanism, encouraging small human safety trials at low doses, but no published human lifespan data. Off-label use is therefore a calculated bet on extrapolation from animal data — not a proven intervention.

Dosing protocols used in longevity practice

Longevity-dosing rapamycin is firmly off-label and experimental. Protocols vary by practitioner, but the most common pattern in the longevity community (as of 2026) is:

• Dose: 3–6 mg once per week (sometimes 5–15 mg in early protocols).
• Frequency: once weekly, occasionally every 10–14 days.
• Timing: typically in the morning, with food.
• Cycling: some practitioners recommend cycling (e.g., 8 weeks on, 4 weeks off) to reduce side-effect risk and prevent adaptation.
• Co-supplements: many users take NMN or NR alongside rapamycin (theoretical — NAD+ restoration while mTOR is inhibited). Some also take metformin on non-rapamycin days.

The rationale for intermittent dosing: it suppresses mTORC1 (the longevity-relevant target) while sparing mTORC2 (whose chronic suppression causes insulin resistance and other metabolic side effects). Once-weekly dosing gives mTORC2 time to recover.

This dosing is not FDA-approved, not validated by clinical trials, and should only be considered with a physician who is knowledgeable about off-label longevity pharmacology. Many users get it through longevity-focused telemedicine clinics.

Side effects and safety concerns

Rapamycin has real side effects, especially at higher chronic doses:

• Mouth ulcers (stomatitis) — very common at any dose, often dose-limiting.
• Hyperlipidemia — raises triglycerides and cholesterol; needs monitoring and often a statin.
• Insulin resistance / hyperglycemia — chronic use impairs glucose tolerance (mTORC2 effect); intermittent dosing reduces this.
• Immune suppression — at high doses, increases infection risk. Paradoxically, at low intermittent doses, rapamycin appears to improve immune function in older adults (the Mannick trials).
• Impaired wound healing — caution around surgery or injury.
• Gastrointestinal — nausea, diarrhea.
• Pneumonitis — rare but serious lung inflammation.
• Skin effects — acne, rash.
• Hematologic — anemia, thrombocytopenia, leukopenia at higher doses.

Most of these are dose-dependent and less frequent at the low weekly doses used in longevity practice. But "less frequent" is not "absent" — anyone taking rapamycin needs regular blood monitoring (lipids, glucose, CBC, kidney and liver function).

Who should not take rapamycin

Rapamycin is contraindicated or inadvisable for:

• Anyone with active infection or recent surgery.
• Pregnant or breastfeeding women (teratogenic in animals).
• People with severe liver disease.
• People with poorly controlled diabetes (rapamycin can worsen glucose tolerance).
• People with active cancer or recent cancer treatment (mTOR's role in cancer is complex — rapamycin analogs are used as cancer drugs in some cases, but the picture is nuanced).
• People who are immunocompromised.
• Children and adolescents (mTOR is critical for growth).
• Anyone planning surgery in the next 6–8 weeks (impaired wound healing).
• People who can't reliably get regular blood monitoring.

For most healthy adults over 40 looking to add a pharmacological anti-aging intervention, rapamycin is the leading candidate — but only with medical supervision and careful monitoring.

How people get rapamycin (legitimate and not)

Rapamycin is a prescription drug. Legitimate ways people obtain it for off-label longevity use:

• Longevity-focused telemedicine clinics — a growing number of online clinics (Maxwell Clinic, Levitation Protocol, others) prescribe rapamycin off-label after intake evaluation, lab work, and consultation. Cost typically $200–500 for the consultation, plus pharmacy cost.
• Forward-thinking primary care or anti-aging physicians — some primary care doctors and anti-aging clinics will prescribe off-label with proper monitoring.
• Compounding pharmacies — sometimes used for dose flexibility.

Illegitimate ways (not recommended):

• "Research chemical" websites — sell rapamycin ostensibly for research use only. Quality is unverified, legal status is questionable, and contamination or mislabeling is a real risk.
• Importing from countries where rapamycin is available without prescription — quality and legal concerns.

We don't recommend any of the illegitimate routes. If you're considering rapamycin, work with a physician who knows the field. This is not a do-it-yourself intervention.

Alternatives and complementary interventions

If rapamycin is too experimental, too risky, or too hard to access, several other mTOR-modulating interventions are available:

• Caloric restriction and intermittent fasting — the original mTOR suppressors. See our fasting guide.
• Protein restriction / methionine restriction — lowers amino acid signaling to mTOR. See our diet guide.
• Metformin — indirectly inhibits mTOR via AMPK activation. Prescription, off-label for non-diabetics. See our metformin guide.
• Exercise (especially Zone 2) — activates AMPK, lowers mTOR signaling. The safest and best-evidenced mTOR modulator available. See our exercise guide.
• Spermidine — induces autophagy via mTOR-independent pathways. See our spermidine guide.
• Resveratrol / pterostilbene — sirtuin activators that complement mTOR inhibition. See our resveratrol guide.

The lifestyle interventions (fasting, exercise, diet) capture much of the mTOR-suppression benefit of rapamycin at zero cost and zero risk. Rapamycin is for those who want to go further pharmacologically.

The future: trials to watch

Several ongoing trials may clarify rapamycin's role in human longevity over the next 5–10 years:

• VAIT (Vaccine and Infection Response in Aging with Rapamycin) — extension of the Mannick trials, testing rapamycin's effect on immune function in older adults.
• Various academic trials — testing rapamycin for specific age-related conditions (cognitive decline, cardiovascular aging, immune senescence).
• The Dog Aging Project — large trial of rapamycin in companion dogs; results will inform translation to humans.
• Longevity-focused clinic data — aggregating outcome data from off-label users via clinics and longevity communities.

None of these are lifespan trials (which would require decades and enormous sample sizes). They are healthspan and biomarker trials, which is the realistic near-term path to validating rapamycin for human use.

The bottom line

Rapamycin is the most credible pharmacological anti-aging candidate, with strong cross-species lifespan data, a clear mechanistic story (mTOR inhibition), and growing human safety data at low intermittent doses. It also has real side effects, requires medical supervision and regular monitoring, and remains firmly experimental for longevity use.

If you're a healthy adult over 40 with access to a longevity-knowledgeable physician, rapamycin at a low weekly dose is worth considering — particularly if you've already optimized the lifestyle fundamentals (exercise, sleep, diet) and want to go further. If you're new to longevity interventions, start with the lifestyle layer first. See our beginner protocol and guide to lowering biological age.

For the broader context, see our David Sinclair supplement list, our Outlive summary, and our supplement stack guide. For a contrast, see our metformin guide.

Recommended products from Amazon

Rapamycin itself is prescription-only and not available on Amazon. But if you're interested in mTOR modulation and want over-the-counter alternatives, these three supplements have the most relevant mechanistic evidence — berberine as an AMPK activator that indirectly inhibits mTOR, EGCG as a mild mTOR modulator, and spermidine as an autophagy inducer via mTOR-independent pathways. These are not replacements for rapamycin — they are lighter-touch interventions for those who don't (yet) have access to prescription options.

DoubleWood Berberine — AMPK activator alternative

Berberine activates AMPK (the cellular low-energy sensor), which indirectly inhibits mTOR — a similar mechanism to metformin, with weaker effect. For people who can't access prescription rapamycin or metformin, berberine is the most-studied over-the-counter mTOR modulator. See our berberine supplements guide for more.

Now Foods EGCG — mild mTOR modulator

EGCG (epigallocatechin gallate) from green tea has been shown to modestly modulate mTOR signaling and induce autophagy. The effect is mild compared to rapamycin, but it's safe, well-tolerated, and has additional cardiovascular and cognitive benefits. See our supplements overview for context.

DoubleWood Spermidine — autophagy inducer (mTOR-independent)

Spermidine induces autophagy via mTOR-independent pathways (inhibition of EP300), making it a complementary approach to mTOR inhibition. Combined with lifestyle interventions (fasting, exercise), spermidine supports the cellular cleanup that rapamycin also promotes. See our spermidine supplements guide for the full comparison.